首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   28257篇
  免费   1915篇
  国内免费   491篇
耳鼻咽喉   137篇
儿科学   846篇
妇产科学   474篇
基础医学   2298篇
口腔科学   364篇
临床医学   3301篇
内科学   6140篇
皮肤病学   309篇
神经病学   1157篇
特种医学   1084篇
外国民族医学   1篇
外科学   2848篇
综合类   3011篇
预防医学   2620篇
眼科学   543篇
药学   3610篇
  8篇
中国医学   812篇
肿瘤学   1100篇
  2023年   833篇
  2022年   1113篇
  2021年   1786篇
  2020年   1563篇
  2019年   1753篇
  2018年   1582篇
  2017年   1069篇
  2016年   836篇
  2015年   838篇
  2014年   1955篇
  2013年   1879篇
  2012年   1353篇
  2011年   1496篇
  2010年   1169篇
  2009年   1069篇
  2008年   1194篇
  2007年   1147篇
  2006年   829篇
  2005年   772篇
  2004年   641篇
  2003年   595篇
  2002年   480篇
  2001年   376篇
  2000年   313篇
  1999年   286篇
  1998年   242篇
  1997年   226篇
  1996年   219篇
  1995年   232篇
  1994年   209篇
  1993年   204篇
  1992年   199篇
  1991年   168篇
  1990年   182篇
  1989年   162篇
  1988年   155篇
  1987年   108篇
  1986年   100篇
  1985年   255篇
  1984年   194篇
  1983年   157篇
  1982年   155篇
  1981年   132篇
  1980年   93篇
  1979年   77篇
  1978年   56篇
  1977年   52篇
  1976年   35篇
  1975年   35篇
  1974年   27篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 探讨纠正低蛋白血症对减少抗结核药物性肝损伤(DILI)发生的作用。方法 2019 年3月~2021 年3 月汕头市中心医院感染病科收治的56例肺结核合并低蛋白血症患者被分为两组,每组28例。给予两组2HRZE/4HR抗结核治疗,另给予观察组输注人血白蛋白纠正低蛋白血症,对照组仅接受抗结核治疗,两组治疗时间均为6个月。使用全自动生化分析仪检测血清白蛋白(ALB)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、碱性磷酸酶(ALP)和总胆红素(TBIL)水平,采用化学发光法检测血清总胆汁酸(TBA)水平。在DILI发生时,给予护肝治疗。在治疗结束时,评定临床转归,进行痰培养和肺部CT检查。结果 观察组结核治愈有效率为92.9%,显著高于对照组的71.4%(P<0.05);观察组痰菌转阴率为91.3%,显著高于对照组的(66.7%,P<0.05),肺部病变吸收率为89.3%,显著高于对照组的64.3%(P<0.05);在治疗期间,观察组DILI发生率为25.0%,显著低于对照组的53.6%(P<0.05);在DILI发生时,7例观察组血清ALB水平为(35.2±4.9)g/L,显著高,15例对照组【(29.6±4.9)g/L g/L,P<0.05】,而血清TBIL水平为(33.6±5.2)μmol/L,显著低于对照组【(45.7±16.6)μmol/L,P<0.05】;在护肝治疗后,观察组血清AST、ALT、ALP、TBIL和TBA水平分别为(39.4±9.8)U/L、(35.1±10.8)U/L、(98.6±16.2)U/L、(17.4±4.6)μmol/L和(81.3±13.7)μmol/L,均显著低于对照组【分别为(64.8±9.9)U/L、(78.0±13.8)U/L、(133.7±22.9)U/L、(26.5±6.8)μmol/L和(96.9±16.4)μmol/L,P<0.05】。结论 补充人血白蛋白及时纠正低蛋白血症,对于肺结核合并低蛋白血症患者能够提高结核治愈率,降低药物性肝损害发生率,值得进一步研究。  相似文献   
2.
3.
4.
ObjectiveNew-onset postoperative atrial fibrillation (POAF) after cardiac surgery is common, with rates up to 60%. POAF has been associated with early and late stroke, but its association with other cardiovascular outcomes is less known. The objective was to perform a meta-analysis of the studies reporting the association of POAF with perioperative and long-term outcomes in patients with cardiac surgery.MethodsWe performed a systematic review and a meta-analysis of studies that presented outcomes for cardiac surgery on the basis of the presence or absence of POAF. MEDLINE, EMBASE, and the Cochrane Library were assessed; 57 studies (246,340 patients) were selected. Perioperative mortality was the primary outcome. Inverse variance method and random model were performed. Leave-one-out analysis, subgroup analyses, and metaregression were conducted.ResultsPOAF was associated with perioperative mortality (odds ratio [OR], 1.92; 95% confidence interval [CI], 1.58-2.33), perioperative stroke (OR, 2.17; 95% CI, 1.90-2.49), perioperative myocardial infarction (OR, 1.28; 95% CI, 1.06-1.54), perioperative acute renal failure (OR, 2.74; 95% CI, 2.42-3.11), hospital (standardized mean difference, 0.80; 95% CI, 0.53-1.07) and intensive care unit stay (standardized mean difference, 0.55; 95% CI, 0.24-0.86), long-term mortality (incidence rate ratio [IRR], 1.54; 95% CI, 1.40-1.69), long-term stroke (IRR, 1.33; 95% CI, 1.21-1.46), and longstanding persistent atrial fibrillation (IRR, 4.73; 95% CI, 3.36-6.66).ConclusionsThe results suggest that POAF after cardiac surgery is associated with an increased occurrence of most short- and long-term cardiovascular adverse events. However, the causality of this association remains to be established.  相似文献   
5.
ObjectiveDeterioration of the native aortic valve function by a late progression of rheumatic disease is not infrequent in patients who underwent rheumatic mitral valve surgery; however, this phenomenon has not been clearly quantified.MethodsA total of 1155 consecutive patients (age 52.0 ± 12.9 years; 807 female) who underwent rheumatic mitral valve surgery without concomitant aortic valve surgery from 1997 to 2015 were enrolled. The primary end point was the composite of progression to severe aortic valve dysfunction or a requirement of subsequent aortic valve replacements during follow-up. To determine the risk factors of the primary outcome, we performed the generalized linear mixed model.ResultsThe baseline severities of aortic valve were none to trivial in 880 patients (76.2%), mild in 256 patients (22.2%), and moderate in 19 patients (1.6%). The latest 1062 echocardiographic assessments (91.9%; median, 81.2 postoperative months; interquartile range, 37.3-132.1 months) demonstrated 26 cases (0.33%/patient-year) meeting the primary end point during follow-up. Cumulative incidence of the primary end point at 10 years was 0.4% ± 0.3% and 7.4% ± 2.5% depending on the presence of mild or greater aortic valve dysfunction at baseline (P < .01). In multivariable analyses, aortic valve peak pressure gradient (odds ratio, 1.14; 95% confidence interval, 1.10-1.20), aortic regurgitation degree (mild over none: odds ratio, 3.26; 95% confidence interval, 1.15-9.23), and time (odds ratio, 1.30; 95% confidence interval 1.19-1.41) were significantly associated with the occurrence of the primary end point.ConclusionsProgression of severe aortic valve dysfunction and the need for aortic valve replacement are uncommon in patients undergoing rheumatic mitral valve surgery. However, such events were relatively common among those with mild or greater aortic valve dysfunction at the time of mitral valve surgery.  相似文献   
6.
7.
BackgroundDiabetes mellitus is a major risk factor for coronary artery disease (CAD) and may provoke structural and functional changes in coronary vasculature. The coronary volume to left ventricular mass (V/M) ratio is a new anatomical parameter capable of revealing a potential physiological imbalance between coronary vasculature and myocardial mass. The aim of this study was to examine the V/M derived from coronary computed tomography angiography (CCTA) in patients with diabetes.MethodsPatients with clinically suspected CAD enrolled in the ADVANCE (Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care) registry and known diabetic status were included. Coronary artery volume and left ventricular myocardial mass were analyzed from CCTA and the V/M ratio was calculated and compared between patients with and without diabetes.ResultsOf the 3053 patients (age 66 ?± ?10 years; 66% male) with known diabetic status, diabetes was present in 21.9%. Coronary volume was lower in patients with diabetes compared to those without diabetes (2850 ?± ?940 ?mm3 vs. 3040 ?± ?970 ?mm3, p ?< ?0.0001), whereas the myocardial mass was comparable between the 2 groups (122 ?± ?33 ?g vs. 122 ?± ?32 ?g, p ?= ?0.70). The V/M ratio was significantly lower in patients with diabetes (23.9 ?± ?6.8 ?mm3/g vs. 25.7 ?± ?7.5 ?mm3/g, p ?< ?0.0001). Among subjects with obstructive CAD (n ?= ?2191, 24.0% diabetics) and non-obstructive CAD (16.7% diabetics), the V/M ratio was significantly lower in patients with diabetes compared to those without (23.4 ?± ?6.7 ?mm3/g vs. 25.0 ?± ?7.3 ?mm3/g, p ?< ?0.0001 and 25.6 ?± ?6.9 ?mm3/g vs. 27.3 ?± ?7.6 ?mm3/g, respectively, p ?= ?0.006).ConclusionThe V/M ratio was significantly lower in patients with diabetes compared to non-diabetics, even after correcting for obstructive coronary stenosis. The clinical value of the reduced V/M ratio in diabetic patients needs further investigation.  相似文献   
8.
目的 探讨中性粒细胞-淋巴细胞计数比率 (NLR)、白蛋白-球蛋白比率(AGR)与食管鳞状细胞癌(ESCC)患者总 生存(OS)期的关系,评估两项指标联合对预测 ESCC 患者预后的应用价值。 方法 本研究回顾性分析了自 2015 年 01 月至 2019 年 12 月间于南通大学附属如皋医院首诊并接受手术治疗的 144 例 ESCC 患者的血常规、血生化检测结果与随访数据。 通过受试者操作特征(ROC)曲线确定 NLR、AGR 的最佳临界值,利用曲线下面积(AUC)评估各指标对 ESCC 患者 OS 期的预 测效能。 通过 Kaplan-Meier 曲线及 Cox 单、多变量回归分析评估两种预测指标的预后价值。 结果 根据期曲线,NLR 与 AGR 预测 ESCC 患者 OS 期的最佳截断值分别为 1. 45 和 1. 48, AUC 值分别为 0. 713 (95%CI = 0. 628 ~ 0. 797)和 0. 673 (95%CI = 0. 584~ 0. 761)。 Kaplan-Meier 曲线展示高 NLR( >1. 45)与低 NLR(≤1. 45)组患者的中位 OS 期分别为 51. 8 个月(95%CI = 36. 2~ 67. 3)和 20. 1 个月(95%CI = 14. 1~ 26. 2),差异有统计学意义(χ 2 = 20. 474, P<0. 001)。 术前低 AGR 值( <1. 48)与 ESCC 患者不良预后显著相关[中位 OS 期:22. 5 个月 (95%CI = 15. 1 ~ 29. 9)比 43. 3 个月 (95%CI = 25. 7 ~ 60. 8)],差异有统计 学意义 (χ 2 = 6. 749, P= 0. 009)。 单、多变量 Cox 分析证实淋巴结转移(HR = 3. 626, 95%CI = 2. 152 ~ 6. 110,P<0. 001)、NLR (HR= 1. 960, 95%CI = 1. 198~ 3. 207,P= 0. 007)与 AGR (HR= 1. 791, 95%CI = 1. 099 ~ 2. 920,P = 0. 019)是 ESCC 患者的独立 预后因素。 此外,我们发现 NLR 联合 AGR 评分(0 分:NLR≤1. 45 且 AGR≥1. 48;1 分: NLR>1. 45 或 AGR<1. 48;2 分:NLR> 1. 45 且 AGR<1. 48 )能够进一步分层 ESCC 患者的预后,患者评分越高,预后越差。 0 分、1 分与 2 分患者的中位 OS 期分别为 56. 6 个月(95%CI = 40. 2~ 67. 3)、29. 9 个月(95%CI = 20. 1~ 39. 8)和 18. 2 个月(95%CI = 12. 1~ 24. 3),组间差异有统计学意义 (0 分比 1 分: χ 2 = 6. 795, P= 0. 009;0 分比 2 分: χ 2 = 19. 529, P<0. 001;1 分比 2 分: χ 2 = 7. 011, P = 0. 008)。 结论 NLR 与 AGR 是评估 ESCC 患者预后的敏感指标,两者联合可以更有效地识别预后不良患者,进而提供更为详尽的预后分层。  相似文献   
9.
ObjectiveTo determine the long-term cardiovascular disease risk of astronauts with spaceflight exposure compared with a well-matched cohort.MethodsNational Aeronautics and Space Administration (NASA) astronauts are selected into their profession based upon education, unique skills, and health and are exposed to cardiovascular disease risk factors during spaceflight. The Cooper Center Longitudinal Study (CCLS) is a generally healthy cohort from a preventive medicine clinic in Dallas, Texas. Using a matched cohort design, astronauts who were selected beginning April 1, 1959, (and each subsequent selection class through 2009) and exposed to spaceflight were matched to CCLS participants who met astronaut selection criteria; 1514 CCLS participants matched to 303 astronauts in a 5-to-1 ratio on sex, date of birth, and age. The outcome of cardiovascular mortality through December 31, 2016, was determined by death certificate or National Death Index.ResultsThere were 11 deaths caused by cardiovascular disease (CVD) among astronauts and 46 among CCLS participants. There was no evidence of increased mortality risk in astronauts (hazard ratio [HR]=1.10; 95% confidence interval [CI], 0.50 to 2.45) with adjustment for baseline cardiovascular covariates. However, the secondary outcome of CVD events showed an increased adjusted risk in astronauts (HR=2.41; 95% CI, 1.26 to 4.63).ConclusionNo increased risk of CVD mortality was observed in astronauts with spaceflight exposure compared with a well-matched cohort, but there was evidence of increased total CVD events. Given that the duration of spaceflight will increase, particularly on missions to Mars, continued surveillance and mitigation of CVD risk is needed to ensure the safety of those who venture into space.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号